GlassScriptPhysician profile
Syed Sameer Nasir
NPI 1801103643
$12,584.00
in general payments reported to CMS, 2019-2025
61 companies · $92.08 in 2025
The $92.08 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,221 · 2020: $3,263 · 2021: $1,969 · 2022: $1,522 · 2023: $2,278 · 2024: $2,238 · 2025: $92.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,390 · Education: $119 · Long Term Medical Supply Or Device Loan: $99.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,390.35 |
| Education | $118.78 |
| Long Term Medical Supply Or Device Loan | $99.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,461.74 | 2019-2024 | Imfinzi, Enhertu |
| Merck Sharp & Dohme LLC | $723.13 | 2019-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $655.55 | 2019-2024 | Opdivo, Opdualag |
| Pfizer INC. | $608.39 | 2019-2024 | |
| Janssen Biotech, INC. | $523.18 | 2020-2024 | Tecvayli, Rybrevant, Talvey |
| Novartis Pharmaceuticals Corporation | $512.32 | 2019-2024 | |
| Gilead Sciences, INC. | $433.65 | 2021-2025 | Trodelvy |
| Amgen INC. | $432.35 | 2019-2022 | |
| Glaxosmithkline, LLC. | $403.83 | 2021-2024 | Zejula, Jemperli, Ojjaara |
| Seagen INC. | $363.95 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Beigene USA, INC. | $322.16 | 2021-2024 | Brukinsa |
| Genentech USA, INC. | $301.81 | 2019-2024 | Venclexta, Tecentriq |
| Rigel Pharmaceuticals, INC. | $296.40 | 2019-2024 | Rezlidhia, Tavalisse |
| Takeda Pharmaceuticals U.S.A., INC. | $294.06 | 2019-2024 | Ninlaro |
| Celgene Corporation | $274.70 | 2019-2024 | Reblozyl, Opdualag |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Nasir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.